SAN LEANDRO, Calif. (PRWEB)
July 22, 2021
Mary Catherine Person and Jim Pursley have joined VIVIO as the company sees unprecedented demand for its specialty drug PBM carve-out services.
Mary Catherine is the former President of HealthSCOPE Benefits, a leading national Third-Party Administrator (TPA), which was sold to UnitedHealthcare in 2019. Ms. Person provided the following thoughts: “As a health plan sponsor, I had firsthand experience with a few specialty drugs accounting for more than 25% of our combined medical and pharmacy plan spend. As a Third-Party Administrator, we saw our customers constantly looking for answers to similar challenges. VIVIO offers plan sponsors the solution to solve the problem of high-cost specialty drugs and I couldn’t be more excited to help expand the mission.”
Jim was the Chief Commercial Officer for Livongo Health, which went public in 2019 before being acquired by Teledoc Health for $18.5B in 2020. Jim now serves as the President of Hinge Health, the leading Digital Musculoskeletal (MSK) Clinic for health plans and employers. Per Mr. Pursley: “Everywhere I go, I hear stories of employers and payors struggling with the rising cost of specialty drugs. Complex markets like this need innovative, transparent solutions that use data to drive personalized care. VIVIO’s next generation Specialty Drug management model efficiently removes waste from the system and improves outcomes for members. They are making significant progress and I am excited to support the VIVIO team.”
Pramod John, Founder and CEO of VIVIO, said “I know that Mary Catherine and Jim will provide unique perspectives as we continue to scale our operations to serve more and more customers. Our Specialty Drug Carve-Out solution works across pharmacy and medical benefits, and nobody understands benefit administration better than Mary Catherine. Jim has focused his career on employee benefit cost containment and improving health outcomes for members; that experience of listening to customers and improving the member experience will be crucial as we grow.”
About VIVIO: VIVIO Precision Care™ fixes the following system problems: identifying expensive drug therapies that don’t work even though they have FDA approval; not knowing if a member is responding adequately to the therapy; doctors not reading the clinical trials themselves; the arbitrary line between pharmacy and medical benefit; and, egregious supply chain waste. VIVIO uses clinical trial, patient, and financial data to drive better patient outcomes while eliminating wasted spend. The company’s carve-out program plugs into an employer’s current carriers and PBMs. 2020 net savings for VIVIO customers was 37%, while both outcomes and member experience significantly improved. In 2020, on average, VIVIO customers experienced a 7.5X ROI on program fees.
Share article on social media or email: